scholarly journals Posttranslational Sodium ion Channel Modifications and the use of Topical Phenytoin in Painful Diabetic Neuropathy (PDN)

2018 ◽  
Vol 3 (1) ◽  
Keyword(s):  
Neuropathic Pain ◽  
Diabetic Neuropathy ◽  
Channel Blocker ◽  
Sodium Ion ◽  
Painful Diabetic Neuropathy ◽  
Sodium Channel Blocker ◽  
Onset Of Action ◽  
Peripheral Neuropathic Pain ◽  
Pain Syndromes ◽  
Number Of Patients

Phenytoin is a broad acting sodium channel blocker we deem fit for topical formulations to treat localized peripheral neuropathic pain. We tested this cream in a number of patients suffering from neuropathic pain syndromes and found it to be especially of use in small fiber neuropathic pain and in painful diabetic neuropathy. The fact that patients report an onset of action within 30 minutes, and the absence of detectable plasma levels of phenytoin, support an intra-epidermal mechanism of action. In this paper, we launch a hypothesis why phenytoin might be of particular use in peripheral neuropathic pain syndromes such as painful diabetic neuropathy

Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy

Pain ◽  
2015 ◽  
Vol 156 (11) ◽  
pp. 2175-2183 ◽  
Author(s):  
Jordi Serra ◽  
W. Rachel Duan ◽  
Charles Locke ◽  
Romà Solà ◽  
Wei Liu ◽  
...  
Keyword(s):  
Diabetic Neuropathy ◽  
Calcium Channel ◽  
Spontaneous Activity ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Painful Diabetic Neuropathy

Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy

Pain ◽  
2003 ◽  
Vol 105 (1) ◽  
pp. 71-78 ◽  
Author(s):  
Peter C.N. Watson ◽  
Dwight Moulin ◽  
Judith Watt-Watson ◽  
Allan Gordon ◽  
John Eisenhoffer
Keyword(s):  
Randomized Controlled Trial ◽  
Neuropathic Pain ◽  
Controlled Release ◽  
Diabetic Neuropathy ◽  
Controlled Trial ◽  
Painful Diabetic Neuropathy ◽  
Randomized Controlled

scholarly journals A Case of Wasp-induced Pain Treated with Topical Phenytoin Cream

2018 ◽  
Vol 1 (3) ◽  
pp. 106-108
Author(s):  
M keppel Hesselink Jan ◽  
Keyword(s):  
Neuropathic Pain ◽  
Sodium Channels ◽  
Mechanism Of Action ◽  
Successful Treatment ◽  
Onset Of Action ◽  
Peripheral Neuropathic Pain ◽  
Wasp Sting ◽  
Competent Cells ◽  
First Time

Phenytoin cream has been evaluated in many patients suffering from peripheral neuropathic pain. Its onset of action has been documented to be within 30 minutes. Its mechanism of action is via the inhibition of sodium channels of the nociceptors in the skin, as well as the inhibition of a number of secondary targets in the skin, such as the keratinocytes and possibly immune-competent cells. Here we describe for the first time the successful treatment of lingering neuralgiformic pains after a wasp sting. Within 20 minutes after application of 10% phenytoin cream, the pain vanished completely. Phenytoin cream might therefore also be of use in the treatment of pain induced by stinging insects.

Peripheral neuropathic pain

2010 ◽  
pp. 45-56
Author(s):  
Tim Nash
Keyword(s):  
Neuropathic Pain ◽  
Diabetic Neuropathy ◽  
Cranial Nerves ◽  
Phantom Limb Pain ◽  
Spinal Nerve ◽  
Phantom Limb ◽  
Spinal Nerve Roots ◽  
Nerve Roots ◽  
Peripheral Neuropathic Pain ◽  
Symptoms And Signs

Damage to peripheral nerves, including cranial nerves and spinal nerve roots, can result in peripheral neuropathic pain Speed of onset and associated symptoms and signs can point towards possible causes Common conditions include diabetic neuropathy, post-herpetic neuralgia, and post-surgical neuropathies including phantom limb pain Less common conditions result from Guillain-Barr syndrome, deficiency states, and toxic neuropathies...

A Peripherally Acting Nav1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain

2009 ◽  
Vol 109 (3) ◽  
pp. 951-958 ◽  
Author(s):  
Erin McGowan ◽  
Scott B. Hoyt ◽  
Xiaohua Li ◽  
Kathryn A. Lyons ◽  
Catherine Abbadie
Keyword(s):  
Neuropathic Pain ◽  
Sodium Channel ◽  
Channel Blocker ◽  
Sodium Channel Blocker ◽  
Rat Models

scholarly journals Neuromidin Attenuates Neuropathic Pain in the Streptozocin-Induced Diabetes Model in Rats

2008 ◽  
Vol 62 (3) ◽  
pp. 85-90
Author(s):  
Vija Kluša ◽  
Juris Rumaks ◽  
Ñina Karajeva
Keyword(s):  
Neuropathic Pain ◽  
Diabetic Neuropathy ◽  
Diabetic Neuropathic Pain ◽  
Cholinergic Mechanism ◽  
Peripheral Neuropathic Pain ◽  
Pain Model ◽  
Diabetes Model ◽  
Neuropathic Pain Model ◽  
New Type ◽  
Anticholinesterase Drug

Neuromidin Attenuates Neuropathic Pain in the Streptozocin-Induced Diabetes Model in Rats Diabetic neuropathy, which affects all peripheral nerves and may cause dramatic pain, is one of the most severe pathologies associated with hyperglycaemia, damage in the blood vessels, and inflammation in nerves. Anticonvulsants and antidepressants are still the most commonly used options to manage diabetic neuropathy. However, to improve clinical benefit in the treatment of diabetic neuropathies, as well as to minimize side effects, search for a new type of drugs to protect/treat neuropathic pain is still important. The aim of this study was to investigate neuromidin (ipidacrine, amiridin, NIK-247), an anticholinesterase drug of tetrahydroaminoacridine series, in the streptozocin (STZ)-induced diabetic neuropathic pain model in rats. Neuromidin was administered per os at daily doses 0.3, 1.0 and 3.0 mg/kg for ten days. The dynamics in the development of hyperalgesia (pain threshold) was measured by algesimeter for five weeks. The data obtained show that neuromidin considerably protects the development of peripheral neuropathic pain caused by STZ. The most active dose was the lowest—0.3 mg/kg. Neuromidin did not affect STZ-hyperglycemia, nor the weight gain in animal groups. Neuromidin per se at the doses 0.3 and 1.0 mg/kg showed a short-term analgesic activity. The cholinergic mechanism of neuromidin may be considered as essential in attenuating of diabetic neuropathic pain; other mechanisms remain to be elucidated.

Butyl 2-(4-[1.1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain

2007 ◽  
Vol 17 (6) ◽  
pp. 1746-1749 ◽  
Author(s):  
Anne-Marie Liberatore ◽  
Jocelyne Schulz ◽  
Christine Favre-Guilmard ◽  
Jacques Pommier ◽  
Jacques Lannoy ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Sodium Channel ◽  
Channel Blocker ◽  
Sodium Channel Blocker
Sign in / Sign up

Export Citation Format

Share Document